Kornimate/medical-research-clean huggingface dataset:
the effect of virtual reality on pain and memory.

Conditions: Healthy Adult

Summary: the effect of virtual reality on pain and memory.

the primary outcome measure was the participants' accuracy of remembering the pattern of a total of five pain stimuli per set. using the quantitative sensory testing "method of limits", each participant selected a temperature they found "painful but tolerable" that they were willing to receive several more times, later in the study. they then received a sequence of five brief stimuli to their wrist, with a brief inter-stimulus interval between each stimulus.

Eligibility criteria:
inclusion criteria: * must be english speaking (but english does not necessarily need to be native/first language). * must be willing to follow our uw approved instructions, exclusion criteria: * not capable of indicating pain intensity * not capable of filling out study measures * non-english-speaking * extreme susceptibility to motion sickness * seizure history * unusual sensitivity or lack of sensitivity to pain * sensitive skin * sensitive feet * migraines * cold symptoms * diabetes * or if you are under 18 years old

Keywords: virtual reality pain distraction
a phase 3 study to evaluate the efficacy and safety of triple therapy with cj-12420 in h. pylori positive patients

Conditions: Helicobacter Pylori Infection

Summary: the current study is designed to demonstrate the non-inferiority of cj-12420-based triple therapy (cj-12420, amoxicillin and clarithromycin) versus lansoprazole-based triple therapy (lansoprazole, amoxicillin and clarithromycin) in h. pylori eradication rate and to evaluate the safety of cj-12420 following oral administration of either triple therapy twice daily for 7 days in h. pylori positive patients.

this is a double blind, randomized, active controlled, phase 3 study. subjects will be randomly assigned to one of the two treatment groups (cj-12420 50mg, lansoprazole 30mg). all subjects will be asked to take 5 tablets include clarithromycin, amoxicillin twice a day for 7 days. after the treatment, ubt test will be conducted to confirm the helicobacter pylori eradication.

Eligibility criteria:
inclusion criteria: * h. pylori-positive at screening * complain of gastric discomfort symptom exclusion criteria: * having received prior therapy for eradication of h. pylori * prior use of proton pump inhibitors (ppis), h2 receptor blockers, at a full dosage within 14 days * prior use of h. pylori eradication effective antibiotics, bismuth within 14 days
photobiomodulation in the treatment of hand-foot syndrome

Conditions: Erythrodysesthesia Syndrome

Summary: a cytotoxic complication caused by chemotherapy is hand-foot syndrome, also known as palmar-plantar erythrodysesthesia (ppe). the mechanism is not yet clear, but it is thought that the chemotherapeutic agent generates cytotoxicity on the acral epidermis. clinically it manifests as erythema and edema on the palms of the hands and feet, dry and scaly skin, accompanied by a sensation of tightness and pain. extreme cases present blisters and ulcerations that may require hospitalization. it can also be accompanied by paresthesias. the main objective will be to evaluate if photobiomodulation is effective in reducing ppe induced by capecitabine and 5-fluorouracil chemotherapy. it will be a 4 week treatment, with 2 groups: g1 - moisturizing cream and photobiomodulation; g2: moisturizing cream and photobiomodulation sham.

methodology: randomized, controlled, double-blind, single-center clinical trial. the study population (40 participants) will be divided into two groups - group 1: moisturizer plus led (light emitting diode) treatment and group 2: moisturizer plus led sham treatment. for the application of led light, antares (ibramed) with p2 led cluster (630 nm) will be applied twice a week in the palmo-plantar areas of the hands and feet (4 j/cm2) for 4 weeks. the palmar-plantar erythrodysesthesia (ppe) degree is the main outcome while the secondary outcomes are the data referring to the chemotherapy treatment plan (chemotherapy dose, need of reducing drug dose or interrupting the treatment) and also the quality of life by using hand-foot syndrome (hsf) questionnaire - hsf-14 and dermatology life questionnaire index (dlqi). ppe grade and chemotherapy plan will be measured prior to the start of treatment with photobiomodulation, in the middle and at the end of it. quality of life questionnaires (hfs-14 - hand-foot syndrome and dlqi - dermatology life questionnaire index) will be applied at the beginning and at the end of the treatment.

Eligibility criteria:
inclusion criteria: * over 18 years of age, * hospitalized or outpatients, * with oncological pathology (confirmed by anatomo-pathological or cytological diagnosis) * undergoing chemotherapy treatment (oral capecitabine and 5-fluorouracil in continuous infusion, following the treatment plans protocolized by the institution: xelox bevacizumab, capecitabine, capecitabine + radiotherapy, folfoxiri, xeliri-bevacizumab, folfox4-bevacizumab , docetaxel-cddp-5-fluorouracil (colony stimulating factors), mfolfirinox q/14 days, flot.) * who develop hand-foot syndrome of greater or equal toxicity to 1 on the ctc scale nci v. 5.0 and on saif scale. et al. for dark skin exclusion criteria: * patients with palmo-plantar skin comorbidities, * autoimmune comorbidities, * amputated limbs, * systemic infection, * localized or regional limb infection, * respiratory isolation, * contact isolation * insulin-requiring diabetics.

Keywords: hand-food syndrome low-level light therapy quality of life
a study of peginterferon alfa-2a (pegasys) in participants with hepatitis b e-antigen (hbeag)-positive chronic hepatitis b virus (hbv)

Conditions: Hepatitis B, Chronic

Summary: this is a study of the efficacy and safety of peginterferon alfa-2a (pegasys) in naive, interferon- or lamivudine-pretreated participants with hbeag-positive chronic hbv. following 48 weeks treatment, there will be a 24 week period of treatment-free follow-up. the anticipated time on study treatment is 3-12 months, and the target sample size is 100-500 individuals.


Eligibility criteria:
inclusion criteria: * adult participants between 18 to 65 years of age * hbeag-positive chronic hbv * treatment-naive, or have received and have not responded to or have relapsed on either conventional interferon or lamivudine therapy. exclusion criteria: * antiviral or interferon-based therapy for chronic hbv within 6 months of enrollment * co-infection with active hepatitis a, c or d virus or with human immunodeficiency virus (hiv) * evidence of decompensated liver disease * medical condition associated with chronic liver disease other than viral hepatitis.
data collection study for the spectrum dynamics multi-purpose czt spect camera

Conditions: Dementia; Parkinson Disease; Pulmonary Hypertension; Heart Diseases; Paget Disease; Bone Diseases; Bone Fracture; Renal Disease; Pulmonary Embolism; Bone Lesion

Summary: this study evaluates spect image data acquired from spectrum dynamics' multi-purpose czt spect-ct camera. all subjects will undergo routine clinical anger spect imaging and an additional spect acquisition on the czt spect camera. additionally some subjects will undergo ct on the czt spect-ct camera. the quality of images from each device will be compared.

the spectrum dynamics multi-purpose czt spect camera is a whole body spect (single photon emission computed tomography) scanner which utilises solid-state cadmium zinc telluride (czt) detectors to visualise injected, or otherwise introduced, radioactivity in the human body. the czt spect camera detects the location and distribution of gamma-emitting radionuclides in the body and produces 3 dimensional cross-sectional images through computed reconstruction of the data for the purpose of determining various metabolic and physiologic functions in the human body. in comparison to conventional sodium iodide (nai) gamma camera (or anger camera) technology, solid state czt technology offers improved energy, spatial and temporal resolution, and higher count rates. improvements in energy resolution and sensitivity thus enable the potential capability for enhanced quantification, simultaneous dual isotope imaging and dynamic imaging acquisition. the camera system also incorporates a multi-slice ct gantry and acquired spect and ct images can be combined to improve image reconstruction by allowing fusion of ct and spect image data for anatomic localisation referencing and ct attenuation correction of the spect image data.

Eligibility criteria:
inclusion criteria: 1. patient is clinically referred for scintigraphy using a radiopharmaceutical in the energy range of 40 - 220 kev emission 2. patient is aged ≥18 years 3. patient condition is stable 4. patient is willing and able to undergo image acquisition on the mpc czt spect camera with integrated ct in addition to standard clinical scintigraphy procedure 5. patient must be willing and able to provide written informed consent 6. patient must be affiliated to a social security scheme exclusion criteria: 1. patient with unstable medical condition 2. patient is pregnant, nursing, or of childbearing potential and is not using adequate contraceptive methods 3. patient is contra-indicated to undergo the scintigraphy imaging procedure for which they have been clinically referred
a study of subcutaneous mircera for the treatment of anemia in dialysis patients.

Conditions: Anemia

Summary: this study will assess the efficacy and safety of subcutaneous (sc) mircera given as maintenance treatment for renal anemia in chronic kidney disease patients on dialysis who were previously receiving sc epoetin. the anticipated time on study treatment is 1-2 years and the target sample size is 100-500 individuals.


Eligibility criteria:
inclusion criteria: * adult patients \>=18 years of age; * chronic renal anemia; * on dialysis therapy for at least 12 weeks before screening; * receiving sc epoetin for at least 8 weeks before screening. exclusion criteria: * women who are pregnant, breastfeeding or using unreliable birth control methods; * administration of another investigational drug within 4 weeks before screening, or during the study period.
study comparing the immune response and safety of fluarix and fluzone influenza vaccines in children

Conditions: Influenza

Summary: the purpose of this study is to compare two influenza vaccines (fluzone and fluarix) in terms of the immune response elicited and safety with a six month follow-up after first vaccination. the protocol posting has been updated in order to comply with the fda amendment act, sep 2007.


Eligibility criteria:
inclusion criteria: * a male or female child age 6 months to \< 18 years at the time of the vaccination; children who may or may not have had previous administration of influenza vaccine in a previous season are acceptable. * subjects having a parent/guardian who the investigator believes can and will comply with the requirements of the protocol should be enrolled in the study. * written informed consent obtained from the subject's parent/guardian; assent obtained in subjects \> 10 years. * female subjects of childbearing potential must agree to take a pregnancy test. exclusion criteria: * use of any investigational or non-registered product (drug or vaccine, other than the study vaccine) within 30 days preceding the administration of the study vaccine, or planned use during the study period. routine, registered childhood vaccinations are not an exclusion. * history of hypersensitivity to any vaccine. * history of allergy or reactions likely to be exacerbated by any component of the vaccine. * acute disease at the time of enrollment. * history of guillain barré syndrome within 6 weeks of receipt of prior inactivated influenza virus vaccine. * pregnant or lactating female. * receipt of an influenza vaccine outside of this study, during current (2006-07) flu season.

Keywords: fluarix influenza
obesity intervention for low-income african american preschoolers

Conditions: Overweight and Obesity

Summary: the purpose of this study is to preliminarily validate a parent-focused obesity intervention program for parents of low-income, african american preschoolers who are currently overweight (\> 85th bmi %tile). half of the participants will receive an intervention that is eight sessions in length and carried out in the participant's home. the sessions will target the nutrition and physical activity knowledge of parents and their motivation for changing parenting related to family eating habits and activity level. the remaining participants will receive an attention comparison control condition (accc), which includes one home visit, 7 newsletters and 4 monthly support phone calls. it is hypothesized that children of parents receiving the intervention will have decreases in bmi %tile, consume more fruits/vegetables and fewer sugary beverages, and engage in more activity as compared to accc.

this study will do a preliminarily validation of a parent-focused obesity intervention program for parents of low-income, african american preschoolers who are currently overweight (\> 85th bmi %tile). participants will be randomly assigned to an intervention or attention control condition. those in the intervention will receive an intervention that is eight sessions in length and carried out in the participant's home. the sessions will target the nutrition and physical activity knowledge of parents and their motivation for changing parenting related to family eating habits and activity level. sessions include psycho-education and skills building exercises. the attention comparison control condition (accc) participants will receive one home visit, 7 newsletters and 4 monthly support phone calls. the content of this condition also focuses on nutrition and activity knowledge, motivation and parenting. outcomes for the intervention and acc conditions will be assessed at baseline, post-intervention and at a 6-month and 1-year followed up. child bmi %tile, consumption of fruits/vegetables and sugary beverages, and activity level will be analyzed to examine intervention effectiveness across time.

Eligibility criteria:
inclusion criteria: * parents of children enrolled in head start preschool in detroit, mi will be included. parents must be 18 years of age or older and their child must be of preschool age, between 3 and 5 years of age. based on recruitment from detroit head start, families will be low-income and of african american descent. children will have a current body mass index percentile at or above the 85th percentile. exclusion criteria: child bmi percentile below the 85th percentile. -
a clinical study to evaluate the efficacy and safety of ckd-351

Conditions: Primary Open Angle Glaucoma; Ocular Hypertension

Summary: the purpose of this study is to evaluate efficacy and safety of ckd-351

multi center, randomized, open-label, active controlled, phase 2 trial, proof of concept study to evaluate the efficacy and safety of ckd-351 in primary open angle glaucoma or ocular hypertension patients

Eligibility criteria:
inclusion criteria: 1. more than the age of 19 years old 2. subjects who has primary open-angle glaucoma or ocular hypertension 3. subjects who sign on an informed consent form willingly exclusion criteria: 1. subjects with intraocular pressure ≥ 35 mmhg at visit 1 or visit 2 (am 09:00) 2. subjects with a maximum corrected visual acuity ≤ 0.3 in the selected evaluation eye at visit 1 or visit 2 3. subjects who were diagnosed as below * aphakia * intraocular lens * acute or chronic closed-angle glaucoma * secondary glaucoma 4. subjects with ocular inflammation or infection within the last 3 months 5. subjects with significant history of ocular trauma during the last 6 months or who underwent surgical opthalmic surgery 6. subjects who received topical or systemic steroids within the last 1 month.

Keywords: primary open-angle glaucoma ocular hypertension ckd-351
a test to predict the hemolytic potential of drugs in g6pd deficiency

Conditions: Glucosephosphate Dehydrogenase Deficiency; Favism

Summary: this study will evaluate a new and safe testing method for identifying medicines that can cause problems in glucose-6-phosphate dehydrogenase (g6pd) deficient individuals. we are looking for volunteers with g6pd deficiency who would be willing to donate blood samples.


Eligibility criteria:
inclusion: * normal clinical evaluation * willing and able to make all scheduled visits exclusion: * pregnant or planning pregnancy * have taken any anti-malarial medication in past month * positive blood tests for hiv and specific types of hepatitis * allergic to primaquine

Keywords: g6pd favism g6pd deficiency hemolysis drug reaction drug-induced hemolysis
executive function in preterm born children: an integrative approach from genetics to brain function

Conditions: Preterm Infants

Summary: hd-eeg and mri measures are used to study the maturation of functional networks in order to identify the neural circuits underlying executive and memory processes in children born preterm. it will be determined whether children born preterm with executive function deficits will have an abnormal connectivity between basal ganglia and cortex due to wm injury. moreover, the development of hd-eeg activity during sleep (coherence and travelling waves) and brain maturation of children and adolescents born preterm will be compared with the respective measures in healthy controls. this is of eminent importance as it helps to understand the nature of executive function and hence, it may help to develop neuroprotective strategies to prevent executive function deficits in these infants.


Eligibility criteria:
inclusion criteria: * schoolchildren between 10 and 12 or 14 and 16 (born between 1996 and 1998 or between 2000 and 2002) * preterm group: born \<32 weeks of gestation * control group: siblings or friends of preterm group in one of the two age groups exclusion criteria: * preterm group: mdi \< 85 at 5 years of age; cerebral palsy * control group: born \<37 weeks of gestation

Keywords: executive functions
early detection of prostate cancer by facs

Conditions: Prostate Cancer; Hyperplasia

Summary: early detection of prostrate cancer and development of metastases. the research will attempt to match the scm test (structuredness of the cytoplasmic matrix) in lymphocytes as an early cancer detection test using florescent activated cell sorting (facs) as a replacement for the cellscan instrument. the test is based on measurement of cellular changes in response to the specific prostate antigen, psa.


Eligibility criteria:
inclusion criteria: experimental group : males between the ages of 60-90 years, with medical diagnosis of prostate cancer according to both clinical and hematological examinations, before receiving any medical treatment. control group 1: males between the ages of 60-90 years, with diagnosed benign prostate hyperplasia -bph. control group 2: males between the ages of 60-90 years, medically diagnosed as healthy. control group 3: males between the ages of 60-90 years, medically diagnosed with another form of cancer, not prostate. exclusion criteria: experimental group: other known cancer or systemic infection. control group 1: other known cancer or systemic infection. control group 2:past hematological disorders nor cancer growth history. other known systemic infection, nor urinary tract infection. patients hospitalized for orthopedic injuries of any type who are otherwise free of urinary tract infections. control group 3:other known systemic infection, nor urinary tract infection. -

Keywords: prostate cancer hyperplasia - bph facs prostate cancer, hyperplasia - bph, malignancy
moleculightdx measurement feature clinical validation

Conditions: Wounds; Wound of Skin

Summary: this is a prospective, single-arm, paired clinical evaluation of the moleculightdx device in the measurement of surface wounds in patients.

the study compares the accuracy of wound measurements (area, length, and width) obtained using the ruler (standard of care) method and the moleculightdx device with a ground truth measurement (reference standard) derived from an expert panel.

Eligibility criteria:
inclusion criteria: * willing to consent * willing to comply with all study procedures and availability for the duration of the study * male or female, aged over 22 years old * presented with diabetic foot ulcers, venous, arterial and pressure ulcers * wound size is greater than 0.5 cm2 * the wound has well-defined wound borders exclusion criteria: * circumferential wound * wound without clearly defined wound borders * wound located in a difficult to reach/measure location * any contra-indication to routine wound care and/or monitoring * wounds with a length greater than 18.5cm or a width greater than 13.5cm. * tunneled or undermined wounds
high-flow needleless valve and dualcap disinfection devices associate with catheter-related bloodstream infection

Conditions: Catheter-related Bloodstream Infection

Summary: the purpose of this study is to investigate whether the usage of high-flow needleless valve and dualcap disinfection devices would reduce the incidence of catheter-related bloodstream infection in hemodialysis patients.


Eligibility criteria:
inclusion criteria: * implanted non-tunneled cuff catheter for any reason and going on blood purified therapy in our centre * have signed information consent form exclusion criteria: * have got bacteremia before catheter implantation * catheter changing in situ
observational study aimed at evaluating the trend of neuropathic pain

Conditions: Neuropathic Pain

Summary: the present study aims to evaluate the trend of neuropathic pain in patients treated with peacetil for a period of two months. neuropathic pain will me assessed through the numeric rating scale (nrs) questionnaire score.


Eligibility criteria:
inclusion criteria: * patients with new or recent diagnosis of acute or chronic neuropathic pain in which the clinician decides to introduce treatment with peacetil according to common clinical practice, belonging to one of the following categories: * dysmetabolic polyneuropathy (e.g. diabetic neuropathy), * chemotherapy treatment neuropathy, * compressive mononeuropathy, * radiculopathy, * postherpetic and non-postherpetic trigeminal neuralgia; * the patient must be able to understand the informed consent of the study; * must adhere to the procedures established by the study; * dn4 score \>4 at t0 (month 0); exclusion criteria: * neurological disorders confounding the primary objective; * clinical condition which during the observational study requires the introduction or modification of the dosage of drugs which are also indicated for the treatment of acute or chronic pain * introduction or modification of the dosage of drugs used to treat acute and chronic neuropathic pain (including other nutraceuticals) from 30 days before the start of the study until the end of the study. * presence of unstable psychiatric illness, cognitive impairment, dementia, or substance abuse that would compromise the participant's ability to provide informed consent, as judged by the investigator; * clinically significant unstable medical condition (e.g., cardiovascular instability, systemic infection, untreated thyroid dysfunction, serious laboratory test abnormality, or clinically significant ecg changes) that would pose a risk to the participant if they were to participate in the study, in the judgment of the 'investigator.

Keywords: neuropathic pain